Integrating expedited partner STI therapy during PrEP delivery for young women
在年轻女性的 PrEP 分娩过程中整合快速伴侣性传播感染治疗
基本信息
- 批准号:10466894
- 负责人:
- 金额:$ 79.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-22 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:Chlamydia trachomatisClinical TrialsCollaborationsCost AnalysisCounselingDapivirineDataData AnalysesDiagnostic testsDisclosureEctopic PregnancyEducational workshopEnrollmentExposure toFemale AdolescentsFrightGoalsGuidelinesHIVHIV-1Health PersonnelHigh Risk WomanIncidenceInfectionInfertilityInterviewKnowledgeLeadMethodsModalityNeisseria gonorrhoeaeOralOutcomeParticipantPelvic Inflammatory DiseasePersonsPlayPolicy MakerPopulationPopulations at RiskPreventionPrevention ResearchProcessProspective cohort studyPublic HealthRecommendationRecurrenceReportingReproductive HealthResearchResourcesRiskRoleSTI preventionSamplingSexual HealthSexual PartnersSexually Transmitted DiseasesSouth AfricaSouth AfricanSustainable DevelopmentSwabSymptomsSyndromeSyphilis SerodiagnosisTarget PopulationsTestingTimeTrichomonas vaginalisVaginaVaginal RingVisitWomanacceptability and feasibilityagedchronic infectioncomparativecostcost estimateexperiencefollow-uphigh standardimplementation evaluationinfection rateinterestlow and middle-income countriesmalemicrocostingneonatal infectionpeerpoint of carepoint of care testingpoint-of-care diagnosticspre-exposure prophylaxispreventrapid testscale upscreeningsexual HIV transmissionsocialstandard of careuptakeyoung woman
项目摘要
PROJECT SUMMARY
Adolescent girls and young women (AGYW) in South Africa have one of the highest HIV-1 incidences globally
and are a key target population for oral pre-exposure prophylaxis (PrEP) to prevent HIV-1 acquisition. In addition,
AGYW seeking PrEP frequently experience high rates of curable sexually transmitted infections (STIs). Current
South African PrEP guidelines recommend syndromic management for STIs, meaning that only women reporting
symptoms will receive treatment. It is well-established that syndromic management is particularly problematic
for women as the vast majority of curable STIs are asymptomatic. Persistent, untreated infections can lead to
serious reproductive health outcomes, including pelvic inflammatory disease, infertility, ectopic pregnancy,
neonatal infections, and increased risk HIV-1 acquisition. The high STI incidence in AGYW, which is on the rise,
emphasizes the need for effective screening strategies to reduce rates of STIs and their associated impact on
sexual and reproductive health outcomes. Among women who are at risk for HIV-1 and interested in initiating
PrEP, point-of-care diagnostic STI testing and expedited partner therapy (EPT) are two strategies that could
have a substantial impact on STI incidence. Few studies have evaluated the feasibility and acceptability of EPT
in low and middle-income countries and, to date, no studies have assessed the implementation of point-of-care
STI testing and EPT in the context of PrEP scale-up. This proposal builds on nearly a decade of collaborative
HIV/STI prevention research to conduct a prospective cohort study of AGYW eligible for PrEP in South Africa in
which we will assess the acceptability of point-of-care STI testing plus EPT and its impact on the incidence of
common curable STIs over 12 months of follow-up (Aims 1 and 2). We will undertake qualitative interviews with
participants and their male partners to identify facilitators and barriers to EPT uptake (Aim 2) and conduct a
comparative cost analysis to estimate the cost per person tested using point-of-care STI testing with and without
EPT incremental to the cost of standard of care (Aim 3). Findings from the proposed research will provide
essential knowledge for national policy makers to advance approaches to STI screening and treatment that will
lead to reductions in STIs and improvements in AGYW sexual reproductive health. The data generated from this
proposal are essential to inform efforts to reduce the burden of STIs and HIV-1 in women achieve the 2030
Sustainable Development Goals, which includes substantial reductions in HIV and STIs in key at-risk populations.
项目摘要
南非的少女和年轻妇女(AGYW)是全球艾滋病毒-1发病率最高的国家之一
并且是预防HIV-1感染的口服暴露前预防(PrEP)的关键目标人群。此外,本发明还提供了一种方法,
寻求PrEP的AGYW经常遇到可治愈的性传播感染(STI)的高比率。电流
南非PrEP指南建议对性传播感染进行综合征管理,这意味着只有报告
症状将得到治疗。众所周知,综合征的管理特别成问题
因为绝大多数可治愈的性传播感染是无症状的。持续的、未经治疗的感染可能导致
严重的生殖健康后果,包括盆腔炎、不孕症、宫外孕,
新生儿感染和增加艾滋病毒-1感染的风险。青少年妇女的性传播感染发病率很高,而且呈上升趋势,
强调需要有效的筛查策略,以降低性传播感染率及其对
性健康和生殖健康成果。在有感染艾滋病毒-1风险并有兴趣开始
PrEP、床旁诊断性STI检测和快速伴侣治疗(EPT)是两种可以
对性传播感染发病率有重大影响。很少有研究评价EPT的可行性和可接受性
在低收入和中等收入国家,迄今为止,没有研究评估了床旁护理的实施情况
在扩大PrEP的背景下进行STI测试和EPT。该提案建立在近十年的合作基础上,
艾滋病毒/性传播感染预防研究,对南非有资格获得PrEP的AGYW进行前瞻性队列研究,
我们将评估床旁STI检测加EPT的可接受性及其对
在12个月的随访中,对常见的可治愈性传播感染进行评估(目标1和2)。我们将进行定性访谈,
参加者及其男性伙伴,以确定促进者和障碍,以EPT吸收(目标2),并进行了一次
比较成本分析,以估计使用床旁STI检测(有和无)进行检测的人均成本
EPT增加了标准治疗的成本(目标3)。拟议研究的结果将提供
为国家决策者提供必要的知识,以推进性传播感染筛查和治疗方法,
减少性传播感染,改善青年女青年的性生殖健康。由此产生的数据
建议是至关重要的,为减少妇女性传播感染和艾滋病毒-1的负担,实现2030年
可持续发展目标,其中包括大幅减少主要高危人群中的艾滋病毒和性传播感染。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jennifer Ellen Balkus其他文献
Jennifer Ellen Balkus的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jennifer Ellen Balkus', 18)}}的其他基金
Integrating expedited partner STI therapy during PrEP delivery for young women
在年轻女性的 PrEP 分娩过程中整合快速伴侣性传播感染治疗
- 批准号:
10158133 - 财政年份:2020
- 资助金额:
$ 79.59万 - 项目类别:
Integrating expedited partner STI therapy during PrEP delivery for young women
在年轻女性的 PrEP 分娩过程中整合快速伴侣性传播感染治疗
- 批准号:
10268256 - 财政年份:2020
- 资助金额:
$ 79.59万 - 项目类别:
Impact of the vaginal microbiome on Chlamydia trachomatis acquisition
阴道微生物组对沙眼衣原体感染的影响
- 批准号:
10082425 - 财政年份:2019
- 资助金额:
$ 79.59万 - 项目类别:
Impact of the vaginal microbiome on Chlamydia trachomatis acquisition
阴道微生物组对沙眼衣原体感染的影响
- 批准号:
10328242 - 财政年份:2019
- 资助金额:
$ 79.59万 - 项目类别:
Development and Validation of an HIV Risk Assessment Tool for African Women
为非洲妇女开发和验证艾滋病毒风险评估工具
- 批准号:
8984923 - 财政年份:2014
- 资助金额:
$ 79.59万 - 项目类别:
相似海外基金
From lymphatics to evaluating resolution therapeutics in clinical trials
从淋巴管到评估临床试验中的解决疗法
- 批准号:
MR/Y013050/1 - 财政年份:2024
- 资助金额:
$ 79.59万 - 项目类别:
Fellowship
RareKids-CAN: Pediatric Rare Disease Clinical Trials and Treatment Network
RareKids-CAN:儿科罕见病临床试验和治疗网络
- 批准号:
495575 - 财政年份:2023
- 资助金额:
$ 79.59万 - 项目类别:
Operating Grants
Unbiased estimation in hierarchical models for Clinical trials
临床试验分层模型中的无偏估计
- 批准号:
2884930 - 财政年份:2023
- 资助金额:
$ 79.59万 - 项目类别:
Studentship
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
- 批准号:
10715568 - 财政年份:2023
- 资助金额:
$ 79.59万 - 项目类别:
NIDA Clinical Trials Network: New York Node
NIDA 临床试验网络:纽约节点
- 批准号:
10855627 - 财政年份:2023
- 资助金额:
$ 79.59万 - 项目类别:
CCTN-CONTRACEPTIVE DEVELOPMENT PROGRAM-NICHD CONTRACEPTIVE CLINICAL TRIALS NETWORK-FEMALE SITES-CORE FUNCTION ACTIVITIES
CCTN-避孕发展计划-NICHD避孕临床试验网络-女性站点-核心功能活动
- 批准号:
10895949 - 财政年份:2023
- 资助金额:
$ 79.59万 - 项目类别:
CONTRACEPTIVE CLINICAL TRIALS NETWORK, CCTN - FEMALE SITES 'CORE FUNCTION ACTIVITIES
避孕临床试验网络,CCTN - 女性站点的核心功能活动
- 批准号:
10891325 - 财政年份:2023
- 资助金额:
$ 79.59万 - 项目类别:
ISimcha Technology Platform for Recruiting a Diverse Population of Older Adults into Clinical Trials
ISimcha 技术平台,用于招募不同的老年人群进行临床试验
- 批准号:
10761602 - 财政年份:2023
- 资助金额:
$ 79.59万 - 项目类别:
Implementing HIV/Cervical Cancer Prevention CASCADE Clinical Trials in Zimbabwe (ZIM-CASCADE)
在津巴布韦实施艾滋病毒/宫颈癌预防 CASCADE 临床试验 (ZIM-CASCADE)
- 批准号:
10758129 - 财政年份:2023
- 资助金额:
$ 79.59万 - 项目类别: